| Literature DB >> 24923339 |
Alexandre R de Mello Schier, Natalia P de Oliveira Ribeiro, Danielle S Coutinho, Sergio Machado, Oscar Arias-Carrión, Jose A Crippa, Antonio W Zuardi, Antonio E Nardi, Adriana C Silva1.
Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24923339 DOI: 10.2174/1871527313666140612114838
Source DB: PubMed Journal: CNS Neurol Disord Drug Targets ISSN: 1871-5273 Impact factor: 4.388